Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
argenx

Immunology-focused biopharmaceutical company

argenx.com
Headquarters
Boston, United States
Founded year
2008
Company type
Public company
Number of employees
2,200–5,000

Last updated

Latest news about argenx

In short: argenx achieved its first year of operating profitability and reported record 2025 sales of $4.2 billion, driven by the expansion of its Vyvgart drug.

Company announcements

argenx

argenx reports Q1 2026 financial results

Global product net sales reach $1.3 billion, up 63% year-over-year. Pipeline updates include upcoming PDUFA for seronegative gMG and topline results for several studies.

Unlock all announcements with a

Media coverage

Yahoo Finance

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following ...

Unlock all articles with a

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

argenx competitors & trending companies

Browse news for competitors to argenx and other trending companies.